B cell maturation antigen (BCMA)-based immunotherapy for multiple myeloma-Reference-Cited by-同舟云学术

B cell maturation antigen (BCMA)-based immunotherapy for multiple myeloma

Published:2019-07-11 Issue:11 Volume:19 Page:1143-1156
ISSN:1471-2598
Container-title:Expert Opinion on Biological Therapy
language:en
Short-container-title:Expert Opinion on Biological Therapy

Author:

Tai Yu-Tzu¹,Anderson Kenneth C¹

Affiliation:

1. LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA

Funder

National Institutes of Health

Publisher

Informa UK Limited

Subject

Clinical Biochemistry,Drug Discovery,Pharmacology

Link

https://www.tandfonline.com/doi/pdf/10.1080/14712598.2019.1641196

Reference99 articles.

1. Multiple myeloma

2. Antibody-Based Therapies in Multiple Myeloma

3. Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological Tumors

4. Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma

5. Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu

Cited by 74 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Bispecific antibodies in the treatment of multiple myeloma;Blood Cancer Journal;2024-09-12

2. Bispecific Antibodies for the Management of Relapsed/Refractory Multiple Myeloma;Cancers;2024-06-26

3. Pathways to therapy resistance: The sheltering effect of the bone marrow microenvironment to multiple myeloma cells;Heliyon;2024-06

4. Practical Aspects of Immunotherapy: A Report from the 20th International Myeloma Society (IMS) Annual Meeting;Clinical Lymphoma Myeloma and Leukemia;2024-06

5. CAR-T Therapy in Multiple Myeloma: Looking Beyond;Hemato;2024-05-31